AstraZeneca Commits £300m to UK Drug Development

AstraZeneca has announced a £300m investment across its UK drug development sites in Cambridge and Macclesfield, restarting a Cambridge programme paused seven months ago. Announced by Prime Minister Sir Keir Starmer during Prime Minister’s Questions on 2 July 2026, the commitment covers a new digital lab in Cheshire and completion of the Rosalind Franklin building on the Cambridge biomedical campus. The move is a notable reversal following broader industry pullback across the UK.

The Cheshire investment funds a new digital lab that will apply artificial intelligence and other emerging technologies to drug development. The Cambridge tranche restarts construction of the Rosalind Franklin building, part of AstraZeneca’s global headquarters at the DISC discovery centre, which had been halted in 2025 when the company paused a £200m investment. AstraZeneca employs more than 4,000 people directly in Cambridge and supports around 6,000 additional roles in the region, alongside approximately 200 science-led partnerships including Cambridge University Hospitals NHS Trust. The company currently sponsors around one third of all pharmaceutical clinical trials run at CUH.

The pause and reversal both traces back to UK medicines pricing policy. AstraZeneca and the government have attributed the renewed commitment to the December 2025 UK-US pharmaceutical deal, under which the NHS will pay 25% more for new medicines and the US has replaced threatened 100% tariffs on branded UK drugs with zero tariffs for three years. NICE’s cost-effectiveness threshold, unchanged since 1999, has been lifted to £35,000 per quality-adjusted life year, with two new cancer drugs already approved under the revised limit.

The underlying commercial signal matters more than the £300m headline. The pricing settlement has moved the UK from an increasingly difficult market for branded pharma to one credible enough to restart pipeline investment, at least for AstraZeneca. Eli Lilly and Merck decisions to follow are the next signals worth watching, alongside the affordability debate that the new NHS pricing settlement is already provoking.

For the latest updates and in-depth insights into the world of Pharmaceuticals, including breakthrough treatments, industry trends, and regulatory news, contact Katie Ginger today!